MCID: ONC002
MIFTS: 54

Onchocerciasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 12 77 54 60 56 45 15 17 74 3
River Blindness 54 3
Infection by Onchocerca Volvulus 12
Onchocerca Volvulus Infection 12
Onchocerciasis, Ocular 74
Robles' Disease 54
Volvulosis 12

Characteristics:

Orphanet epidemiological data:

60
onchocerciasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11678
ICD9CM 36 125.3
MeSH 45 D009855
NCIt 51 C34861
SNOMED-CT 69 38539003
ICD10 34 B73
MESH via Orphanet 46 D009855 D015827
ICD10 via Orphanet 35 B73
UMLS via Orphanet 75 C0029001 C0029002
Orphanet 60 ORPHA2737

Summaries for Onchocerciasis

NIH Rare Diseases : 54 Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. Repeated bites by infected flies increase the number of adult worms and larvae. Chronic skin onchocerciasis (onchodermatitis) causes itching, a rash with small pimples (papular rash), scarring, and thickened, leathery skin (lichenification). Other symptoms may develop over time and might include saggy skin (such as ''hanging groin''), patchy areas of much lighter colored skin (leopard skin), ichthyosis-like lesions (''lizard skin''), darkening of the skin, and very severe itching. The eye infection is known as river blindness because the blackfly carrying the parasite lives near fast-flowing waters. Symptoms of an eye infection may include itchy eyes, red eyes, and sensitivity to light (photophobia). In some cases, the larvae may infect the optic nerve. As the common name suggests, infection of the eye by onchocerciasis can lead to vision loss and eventually blindness. The disease is caused by the parasitic worm Onchocerca volvulus and is transmitted by the bite of an infected black fly. About 90% of the cases occur in Africa. Treatment aims to remove the larvae (microfilariae), to improve symptoms, to prevent progression of eye lesions, and to stop the parasite from being passed back to black flies so other people do not become infected. Medications include an anti-parasitic known as ivermectin, antibiotics such as rifampin, azithromycin, and doxycycline, and, another recently approved anti-parasitic drug, Moxidectin.

MalaCards based summary : Onchocerciasis, also known as river blindness, is related to filariasis and filarial elephantiasis. An important gene associated with Onchocerciasis is RBP3 (Retinol Binding Protein 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ivermectin and Anticonvulsants have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Disease Ontology : 12 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

CDC : 3  

Wikipedia : 77 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 filariasis 31.3 CCL5 IL2 IL5
2 filarial elephantiasis 31.2 IL4 IL5 SRCIN1
3 intestinal volvulus 30.7 CALR IL5 SRCIN1
4 elephantiasis 30.5 RNASE3 SRCIN1
5 chorioretinitis 30.3 RBP3 SRCIN1
6 wells syndrome 30.2 IL2 IL5 RNASE3
7 schistosomiasis 30.2 IL13 IL2 IL4 IL5 RNASE3
8 dermatitis 30.2 CCL11 IL13 IL4 IL5
9 tetanus 30.1 IL13 IL2 IL4 IL5
10 skin disease 29.7 CCL11 IL13 IL4 IL5 RNASE3
11 ige responsiveness, atopic 29.7 IL13 IL4 IL5 RNASE3
12 urinary schistosomiasis 29.6 EPX IL13 IL4 IL5 RNASE3
13 leishmaniasis 29.6 IL13 IL4 IL5 MPI
14 trypanosomiasis 29.5 CALR CCL5 IL2 IL4
15 malaria 29.4 CCL11 CCL5 IL13 IL2 IL4 IL5
16 parasitic helminthiasis infectious disease 29.0 IL13 IL2 IL4 IL5 RNASE3 SRCIN1
17 dermatitis, atopic 28.4 CCL11 CCL5 EPX IL13 IL2 IL4
18 loiasis 11.5
19 epilepsy 10.7
20 virus associated hemophagocytic syndrome 10.4 IL2 IL4
21 scleritis 10.4 IL4 IL5
22 loeffler endocarditis 10.4 IL5 RNASE3
23 autoimmune vasculitis 10.4 IL2 IL4
24 egg allergy 10.4 IL4 IL5
25 sulfamethoxazole allergy 10.4 IL4 IL5
26 trichinosis 10.3 IL4 IL5
27 cow milk allergy 10.3 IL5 RNASE3
28 non-suppurative otitis media 10.3 IL4 IL5
29 sinusitis 10.3 IL5 RNASE3
30 jak3-deficient severe combined immunodeficiency 10.3 IL2 IL4
31 papillary conjunctivitis 10.3 CCL11 IL4
32 eosinophilic granuloma 10.3 EPX RNASE3
33 toxic oil syndrome 10.3 IL4 IL5
34 maxillary sinusitis 10.3 CCL5 RNASE3
35 autoimmune gastritis 10.3 IL2 IL4
36 pemphigoid gestationis 10.3 CCL11 IL5
37 conjunctival nevus 10.3 EPX RNASE3
38 vulvovaginal candidiasis 10.3 IL2 IL4
39 chronic meningitis 10.3 CCL11 IL5
40 autoimmune disease 10.3 IL2 IL4 RBP3
41 cough variant asthma 10.3 IL4 IL5 RNASE3
42 autoimmune disease of eyes, ear, nose and throat 10.2 CCL5 RBP3
43 intrinsic asthma 10.2 IL4 IL5 RNASE3
44 cytokine deficiency 10.2 IL13 IL5
45 orofacial granulomatosis 10.2 CCL5 IL4
46 milk allergy 10.2 IL4 IL5 RNASE3
47 gaucher disease, type ii 10.2 IL2 IL4 IL5
48 eales disease 10.2 IL4 RBP3
49 penicillin allergy 10.2 IL13 IL4
50 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL13 IL5

Graphical network of the top 20 diseases related to Onchocerciasis:



Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 70288-86-7 6474909
2 Anticonvulsants Phase 4,Phase 2
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5
Albendazole Approved, Vet_approved Phase 3,Not Applicable 54965-21-8 2082
6 Vitamins Phase 3,Phase 2
7 Anthelmintics Phase 3,Phase 2,Phase 1,Not Applicable
8 Antimitotic Agents Phase 3,Not Applicable
9 Antiprotozoal Agents Phase 3,Phase 2,Not Applicable
10 Milbemycin Phase 3,Phase 2
11
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
12
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
13
Rifampicin Approved Phase 2 13292-46-1 5381226 5458213
14
Azithromycin Approved Phase 2 83905-01-5 55185 447043
15
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 2,Not Applicable 90-89-1 3052
16
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
18
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
19
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
20 Antimanic Agents Phase 2
21 Central Nervous System Depressants Phase 2
22 Psychotropic Drugs Phase 2
23 Sodium Channel Blockers Phase 2
24 Nutrients Phase 2
25 Vitamin B Complex Phase 2
26 Neurotransmitter Agents Phase 2
27 Trace Elements Phase 2
28 Micronutrients Phase 2
29 Vitamin B9 Phase 2
30 Folate Phase 2
31 GABA Agents Phase 2
32 Tranquilizing Agents Phase 2
33 Vitamin B 6 Phase 2
34 Diuretics, Potassium Sparing Phase 2
35 Anti-Bacterial Agents Phase 2
36 Nucleic Acid Synthesis Inhibitors Phase 2
37 Cytochrome P-450 CYP3A Inducers Phase 2
38 Antibiotics, Antitubercular Phase 2
39 Antitubercular Agents Phase 2
40 Artemisinins Phase 2
41 Antimalarials Phase 2
42 Artemisinine Phase 2
43 Protein Kinase Inhibitors Phase 2
44 Imatinib Mesylate Phase 2 220127-57-1 123596
45
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
46
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
47
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
48
Piperazine Approved, Vet_approved 110-85-0 4837
49
Mebendazole Approved, Vet_approved 31431-39-7 4030
50
Sodium Citrate Approved, Investigational 68-04-2

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Completed NCT03052998 Phase 4 Ivermectin
2 Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy Active, not recruiting NCT03852303 Phase 4 ivermectin
3 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
4 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
5 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
6 Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis Not yet recruiting NCT03876262 Phase 3 Moxidectin;Ivermectin
7 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
8 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
9 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
10 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
11 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
12 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
13 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
14 Prevalence of LF Infection in Districts Not Included in LF Control Activities Completed NCT03131401
15 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
16 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
17 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
18 Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis Completed NCT02899936 Not Applicable 3 drug dose - IDA;2 drug dose - DA
19 Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia Completed NCT00349323
20 Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District Recruiting NCT03653975
21 Host Response to Infection and Treatment in Filarial Diseases Recruiting NCT00001230
22 Lymphatic Filariasis (LF) in Ivory Coast Active, not recruiting NCT02974049 Not Applicable Albendazole;Ivermectin;Diethylcarbamazine
23 Ocular Changes After Ivermectin - (DOLF IVM/Oncho) Enrolling by invitation NCT03517462 Not Applicable Ivermectin 3Mg Tab

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

MalaCards organs/tissues related to Onchocerciasis:

42
Skin, Eye, Testes, Neutrophil, Lymph Node, T Cells, Breast

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 1849)
# Title Authors Year
1
Epidemiological evidence concerning the association between onchocerciasis and epilepsy. ( 30885705 )
2019
2
Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon. ( 30890155 )
2019
3
Onchocerciasis associated epilepsy-A question of causality. ( 30711144 )
2019
4
High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment. ( 30711145 )
2019
5
Comprehensive management of epilepsy in onchocerciasis-endemic areas: lessons learnt from community-based surveys. ( 30738437 )
2019
6
Low prevalence of epilepsy and onchocerciasis after more than 20 years of ivermectin treatment in the Imo River Basin in Nigeria. ( 30670093 )
2019
7
Onchocerciasis-associated epilepsy. ( 30587287 )
2019
8
Onchocerciasis-associated epilepsy - Authors' reply. ( 30587288 )
2019
9
Clinical presentations of onchocerciasis-associated epilepsy (OAE) in Cameroon. ( 30513438 )
2019
10
Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test. ( 30699120 )
2019
11
Boron-Pleuromutilins as Anti-Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. ( 30730745 )
2019
12
Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. ( 30867321 )
2019
13
Entomological assessment of the transmission following recrudescence of onchocerciasis in the Comoé Valley, Burkina Faso. ( 30646934 )
2019
14
Differences in the Clinical and Laboratory Features of Imported Onchocerciasis in Endemic Individuals and Temporary Residents. ( 30761981 )
2019
15
Loa loa microfilariae in skin snips: consequences for onchocerciasis monitoring and evaluation in L. loa endemic areas. ( 30861060 )
2019
16
In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. ( 30867498 )
2019
17
Comparison of Reported and Survey-Based Coverage in Onchocerciasis Programs over a Period of 8 Years in Cameroon and Uganda. ( 30915956 )
2019
18
Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon. ( 29921312 )
2018
19
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 29348597 )
2018
20
High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20A years of community directed treatment with ivermectin. ( 29921319 )
2018
21
Proof-of-Concept Rapid Diagnostic Test for Onchocerciasis: Exploring Peptide Biomarkers and the Use of Gold Nanoshells as Reporter Nanoparticles. ( 29547260 )
2018
22
Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 years. ( 29605818 )
2018
23
Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis? ( 29210346 )
2018
24
Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes. ( 29966535 )
2018
25
Geographical distribution and species identification of human filariasis and onchocerciasis in Bioko Island, Equatorial Guinea. ( 29289559 )
2018
26
Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world. ( 29642939 )
2018
27
Onchocerciasis prevalence, human migration and risks for onchocerciasis elimination in the Upper Mouhoun, NakambAc and Nazinon river basins in Burkina Faso. ( 29782820 )
2018
28
Modelling the impact of larviciding on the population dynamics and biting rates of Simulium damnosum (s.l.): implications for vector control as a complementary strategy for onchocerciasis elimination in Africa. ( 29843770 )
2018
29
Rethinking the serological threshold for onchocerciasis elimination. ( 29543797 )
2018
30
Interruption of onchocerciasis transmission in Bioko Island: Accelerating the movement from control to elimination in Equatorial Guinea. ( 29723238 )
2018
31
Elimination of onchocerciasis in Ecuador: findings of post-treatment surveillance. ( 29690907 )
2018
32
Evaluation of onchocerciasis control in the Upper Denkyira East municipal in the forest area of Ghana: Responses of participants and distributors to the CDTI programme. ( 29932933 )
2018
33
Report of the first international workshop on onchocerciasis-associated epilepsy. ( 29580280 )
2018
34
Sara Lustigman: Developing a vaccine to accelerate onchocerciasis elimination. ( 29174373 )
2018
35
Corrigendum to: 'Onchocerciasis: the beginning of the end'. ( 29659849 )
2018
36
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria. ( 29943709 )
2018
37
"Cross-border collaboration in onchocerciasis elimination in Uganda: progress, challenges and opportunities from 2008 to 2013". ( 29409509 )
2018
38
Onchocerciasis associated epilepsy: An important neglected public health problem. ( 29325732 )
2018
39
Impact of five annual rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone. ( 29628019 )
2018
40
How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control. ( 29860291 )
2018
41
Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin. ( 30501640 )
2018
42
Baseline characterization of epilepsy in an onchocerciasis endemic area of the Democratic Republic of Congo. ( 30468846 )
2018
43
High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: A community-based survey. ( 30468964 )
2018
44
Community perceptions of epilepsy and its treatment in an onchocerciasis endemic region in Ituri, Democratic Republic of Congo. ( 30509330 )
2018
45
The effect of bi-annual community-directed treatment with ivermectin on the incidence of epilepsy in onchocerciasis endemic villages in South Sudan: a study protocol. ( 30424817 )
2018
46
Clinical characteristics of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan. ( 30340162 )
2018
47
Onchocerciasis and epilepsy: a causal relationship? ( 30268644 )
2018
48
The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study. ( 30268645 )
2018
49
Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study. ( 30293530 )
2018
50
Onchocerciasis-Associated Epilepsy with Head Nodding Seizures-Nodding Syndrome: A Case Series of 15 Patients from Western Uganda, 1994. ( 30226148 )
2018

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CALR CCL11 CCL5 EPX IL13 IL2
2
Show member pathways
13.53 CCL11 CCL5 CCL7 IL13 IL2 IL4
3
Show member pathways
13.37 CCL11 CCL5 CCL7 IL13 IL2 IL4
4
Show member pathways
13.25 CCL11 CCL5 CCL7 IL13 IL2 IL4
5
Show member pathways
13.2 CCL11 CCL5 IL13 IL2 IL4 IL5
6
Show member pathways
13.13 CCL11 CCL5 CCL7 IL13 IL2 IL4
7 12.68 IL13 IL2 IL4 IL5
8
Show member pathways
12.6 CALR CCL11 EPX IL13 IL2 IL4
9
Show member pathways
12.46 IL13 IL2 IL4 IL5
10
Show member pathways
12.43 CCL5 IL13 IL2 IL4
11
Show member pathways
12.26 IL13 IL2 IL4 IL5
12
Show member pathways
12.21 CCL11 CCL7 IL13 IL4 IL5
13
Show member pathways
12.13 IL13 IL2 IL4 IL5
14
Show member pathways
11.91 IL13 IL2 IL5
15
Show member pathways
11.88 CCL11 CCL5 CCL7
16
Show member pathways
11.88 CCL11 CCL5 CCL7 IL13 IL2 IL4
17 11.87 IL2 IL4 IL5
18 11.86 CCL11 IL13 IL4
19 11.73 IL13 IL2 IL4 IL5
20 11.7 IL13 IL2 IL4 IL5
21
Show member pathways
11.64 IL2 IL4 IL5
22 11.62 CCL11 CCL5 IL13 IL2 IL4
23 11.55 CCL11 IL4 IL5
24 11.43 CCL5 IL13 IL4
25 11.35 CCL11 CCL5 IL13 IL4 IL5
26 11.24 IL2 IL4 IL5
27 11.22 IL13 IL4 IL5
28 11.2 IL13 IL2 IL4 IL5
29 11.12 IL13 IL2 IL4 IL5
30 11.1 IL13 IL2
31 11.02 CCL11 IL13 IL2 IL4 IL5
32 10.9 CCL11 CCL5 CCL7 IL13 IL2 IL4
33 10.4 CCL11 CCL5 CCL7 IL13 IL2 IL4

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CALR CCL11 CCL5 CCL7 EPX IL13
2 extracellular space GO:0005615 9.36 CALR CCL11 CCL5 CCL7 EPX IL13
3 cell GO:0005623 9.33 CCL11 CCL7 IL2

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 CCL11 CCL5 CCL7 IL13 IL5
2 chemotaxis GO:0006935 9.78 CCL11 CCL5 CCL7
3 cellular response to tumor necrosis factor GO:0071356 9.77 CCL11 CCL5 CCL7
4 cellular response to interferon-gamma GO:0071346 9.75 CCL11 CCL5 CCL7
5 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL5 CCL7
6 cellular response to interleukin-1 GO:0071347 9.72 CCL11 CCL5 CCL7
7 chemokine-mediated signaling pathway GO:0070098 9.71 CCL11 CCL5 CCL7
8 positive regulation of T cell proliferation GO:0042102 9.69 CCL5 IL2 IL4
9 monocyte chemotaxis GO:0002548 9.67 CCL11 CCL5 CCL7
10 cellular calcium ion homeostasis GO:0006874 9.67 CALR CCL11 CCL5 CCL7
11 cytokine-mediated signaling pathway GO:0019221 9.63 CCL11 CCL5 IL13 IL2 IL4 IL5
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 CCL5 IL13 IL2 IL4
13 positive regulation of JAK-STAT cascade GO:0046427 9.61 CCL5 IL5
14 lymphocyte chemotaxis GO:0048247 9.61 CCL11 CCL5 CCL7
15 positive regulation of T cell differentiation GO:0045582 9.6 IL2 IL4
16 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL5
17 eosinophil chemotaxis GO:0048245 9.58 CCL11 CCL5 CCL7
18 positive regulation of isotype switching to IgG isotypes GO:0048304 9.57 IL2 IL4
19 positive regulation of B cell proliferation GO:0030890 9.56 IL13 IL2 IL4 IL5
20 positive regulation of natural killer cell chemotaxis GO:2000503 9.52 CCL5 CCL7
21 immune response GO:0006955 9.5 CCL11 CCL5 CCL7 IL13 IL2 IL4
22 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL13 IL4
23 regulation of signaling receptor activity GO:0010469 9.17 CCL11 CCL5 CCL7 IL13 IL2 IL4

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 IL2 IL4 IL5
2 cytokine receptor binding GO:0005126 9.37 IL13 IL4
3 chemokine activity GO:0008009 9.33 CCL11 CCL5 CCL7
4 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL7
5 cytokine activity GO:0005125 9.17 CCL11 CCL5 CCL7 IL13 IL2 IL4
6 CCR chemokine receptor binding GO:0048020 9.13 CCL11 CCL5 CCL7

Sources for Onchocerciasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....